Pharmakologisches Neuroenhancement: Substanzen und Epidemiologie

• Literatur

• 1 Franke AG, Lieb K. [Pharmacological neuroenhancement and brain doping: chances and risks]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010; 53: 853-859
• 2 Cakic V. Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology. J Med Ethics 2009; 35: 611-615
• 3 Farah MJ, Illes J, Cook-Deegan R. et al. Neurocognitive enhancement: what can we do and what should we do?. Nat Rev Neurosci 2004; 5: 421-425
• 4 Maher B. Poll results: look who's doping. Nature 2008; 452: 674-675
• 5 Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 1992; 17: 139-170
• 6 Ferre S, Ciruela F, Borycz J. et al. Adenosine A1–A2A receptor heteromers: new targets for caffeine in the brain. Front Biosci 2008; 13 2391-2399
• 7 Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 2004; 61: 857-872
• 8 Marley E, Nistico G. Effects of catecholamines and adenosine derivatives given into the brain of fowls. Br J Pharmacol 1972; 46: 619-636
• 9 Franke AG, Heinz I, Lieb K. et al. Gebrauch von Ginkgo biloba bei Älteren in Deutschland. Posterabstract.. Berlin: DGPPN; 2010
• 10 Foster S, Yue C. Herbal emissaries: bringing Chinese herbs to the West: a guide to gardening, herbal wisdom, and well-being. Rochester, Vt: Healing Arts Press; 1992
• 11 Smith JV, Burdick AJ, Golik P. et al. Anti-apoptotic properties of Ginkgo biloba extract EGb 761 in differentiated PC12 cells. Cell Mol Biol (Noisy-le-grand) 2002; 48: 699-707
• 12 Smith JV, Luo Y. Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol 2004; 64: 465-472
• 13 Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009; CD003120
• 14 Franke AG, Konrad A, Lieb K. et al. [Stimulant and non-stimulant medication in current and future therapy for ADHD]. Fortschr Neurol Psychiatr 0
• 15 Wilens TE, Adler LA, Adams J. et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47: 21-31
• 16 Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2008; 28: 46-53
• 17 Oades RD, Sadile AG, Sagvolden T. et al. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. Dev Sci 2005; 8: 122-131
• 18 Repantis D, Schlattmann P, Laisney O. et al. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacol Res 2010; 62: 187-206
• 19 Biederman J, Monuteaux MC, Spencer T. et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008; 165: 597-603
• 20 Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med 2008; 10: 111
• 21 Gould MS, Walsh BT, Munfakh JL. et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009; 166: 992-1001
• 22 Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008; 33: 1477-1502
• 23 Wesensten NJ, Killgore WD, Balkin TJ. Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J Sleep Res 2005; 14: 255-266
• 24 Killgore WD, Kahn-Greene ET, Grugle NL. et al. Sustaining executive functions during sleep deprivation: A comparison of caffeine, dextroamphetamine, and modafinil. Sleep 2009; 32: 205-216
• 25 Franke AG, Lieb K, Fellgiebel A. [From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer’s disease]. Fortschr Neurol Psychiatr 2009; 77: 326-333
• 26 Repantis D, Laisney O, Heuser I. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 2010; 61: 473-481
• 27 Repantis D, Schlattmann P, Laisney O. et al. Antidepressants for neuroenhancement in healthy individuals: a systematic review. Poiesis Prax 2009; 6: 139-174
• 28 Partridge BJ, Bell SK, Lucke JC. et al. Smart drugs “as common as coffee”: media hype about neuroenhancement. PLoS ONE 2011; 6: e28416
• 29 Franke AG, Benerz C, Christmann M. et al. Attitudes towards cognitive enhancement in users and non-users of stimulants for cognitive enhancement: a pilot study. AJOB Prim Res 2012; 3: 48-57
• 30 Deutsche Angestelltenkrankenkasse (DAK). Gesundheitsreport 2009. Analyse der Arbeitsunfähigkeitsdaten. Schwerpunktthema Doping am Arbeitsplatz. Berlin, Hamburg: IGES Institut GmbH; 2009
• 31 Franke AG, Bonertz C, Christmann M. et al. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 2011; 44: 60-66
• 32 Franke AG, Bonertz C, Christmann M. et al. Use of coffee, caffeinated drinks and caffeine tablets for cognitive enhancement in pupils and students. Pharmacopsychiatry 2011; 44: 331-338
• 33 Striegel H, Ulrich R, Simon P. Randomized response estimates for doping and illicit drug use in elite athletes. Drug Alcohol Depend 2010; 106: 230-232
• 34 Lieb K. Neuroenhancement mit Medikamenten. In: Duriska M, Ebner-Priemer U, Stolle M. Hrsg. Rückenwind. Was Studis gegen Stress tun können. Ettlingen: Kraft; 2011: 94-97
• 35 Hildt E, Franke AG, Lieb K. Pharmakologisches Neuroenhancement: Informationsquellen und Akzeptanz unter Studierenden. Nervenheilkunde 2011; 10: 833-837
• 36 Huss M, Holling H, Kurth BM. et al. How often are German children and adolescents diagnosed with ADHS? Prevalence based on the judgment of health care professionals: results of the German health and examination survey (KiGGS). Eur Child Adolesc Psychiatry 2008; 17: 52-58
• 37 Greely H, Sahakian B, Harris J. et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008; 456: 702-705
• 38 Synofzik M. Ethically justified, clinically applicable criteria for physician decision-making in psychopharmacological enhancement. Neuroethics 2009; 2: 89-102